Exosens - Public Comps and Valuation Multiples

Exosens Overview

About Exosens

Exosens SA is a high-tech company specializing in electro-optical technologies for amplification, detection, and imaging. It offers products such as night vision tubes, ultraviolet cameras, travelling wave tubes, and various detectors for defense, life sciences, nuclear, and industrial sectors. With multiple production sites in Europe and North America. The company’s activities are organized into two main segments: Amplification, which focuses on electron or electromagnetic wave amplification systems mainly used in defense night vision equipment and generates the majority of its revenue, and Detection & Imaging, which provides high value-added components for commercial markets such as nuclear power, research, and industrial applications.

Founded

2021

HQ

Employees

1.8K+

Website

exosens.com

Sectors

Electronic Equipment
Sensors & Instruments
DeepTech

Financials

LTM Revenue $525M

LTM EBITDA $158M

EV

$2.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Exosens Financials

As of September 2025, Exosens reported last 12-month revenue of $525M and EBITDA of $158M.

In the same period, Exosens generated $367M in LTM gross profit and $67.9M in net income.

See Exosens valuation multiples based on analyst estimates

Exosens P&L

In the most recent fiscal year, Exosens reported revenue of $456M and EBITDA of $128M.

Exosens expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Exosens valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$525M	XXX	$456M	XXX	XXX	XXX
Gross Profit	$367M	XXX	$331M	XXX	XXX	XXX
Gross Margin	70%	XXX	73%	XXX	XXX	XXX
EBITDA	$158M	XXX	$128M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	28%	XXX	XXX	XXX
EBIT	$123M	XXX	$93.2M	XXX	XXX	XXX
EBIT Margin	24%	XXX	20%	XXX	XXX	XXX
Net Profit	$67.9M	XXX	$35.5M	XXX	XXX	XXX
Net Margin	13%	XXX	8%	XXX	XXX	XXX
Net Debt	XXX	XXX	$151M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Exosens including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $525M. EBITDA for the last twelve months was $158M. In the most recent fiscal year, Exosens achieved $456M in revenue and $128M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$525M	Analyst estimates available to subscribers	$456M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$367M	Analyst estimates available to subscribers	$331M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	69.9% gross margin	Analyst estimates available to subscribers	72.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$158M	Analyst estimates available to subscribers	$128M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	30.0% EBITDA margin	Analyst estimates available to subscribers	28.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$123M	Analyst estimates available to subscribers	$93.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	23.5% EBIT margin	Analyst estimates available to subscribers	20.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$67.9M	Analyst estimates available to subscribers	$35.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.9% net profit margin	Analyst estimates available to subscribers	7.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$151M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Exosens

This financial data table provides comprehensive performance metrics for Exosens, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Exosens generated $525M in revenue over the last twelve months.
The company achieved $158M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $367M.
Net income over the last twelve months reached $67.9M.

Fiscal Year Performance

In the most recent fiscal year, Exosens reported $456M in total revenue.
Fiscal year EBITDA was $128M.
The company maintained a gross profit margin of 72.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 28.0%.
Net profit margin reached 7.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Exosens. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Exosens Stock Performance

Exosens has current market cap of EUR 2.3B (or $2.6B), and EV of EUR 2.4B (or $2.8B).

Market Cap Evolution

Exosens Stock Data

As of October 17, 2025, Exosens's stock price is EUR 44 (or $51).

See Exosens trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.8B	$2.6B	XXX	XXX	XXX	XXX	$1.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Exosens Valuation Multiples

Exosens's trades at 6.1x EV/Revenue multiple, and 21.7x EV/EBITDA.

See valuation multiples for Exosens and 15K+ public comps

Exosens Financial Valuation Multiples

As of October 17, 2025, Exosens has market cap of $2.6B and EV of $2.8B.

Equity research analysts estimate Exosens's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Exosens has a P/E ratio of 38.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.6B	XXX	$2.6B	XXX	XXX	XXX
EV (current)	$2.8B	XXX	$2.8B	XXX	XXX	XXX
EV/Revenue	5.3x	XXX	6.1x	XXX	XXX	XXX
EV/EBITDA	17.6x	XXX	21.7x	XXX	XXX	XXX
EV/EBIT	22.4x	XXX	29.7x	XXX	XXX	XXX
EV/Gross Profit	7.6x	XXX	n/a	XXX	XXX	XXX
P/E	38.4x	XXX	73.4x	XXX	XXX	XXX
EV/FCF	48.1x	XXX	43.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Exosens Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Exosens Margins & Growth Rates

Exosens's last 12 month revenue growth is 14%

Exosens's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Exosens's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Exosens's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Exosens and other 15K+ public comps

Exosens Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	14%	XXX	16%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	30%	XXX	XXX	XXX
Rule of 40	41%	XXX	42%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	66%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial